{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T02:05:04Z","timestamp":1773885904650,"version":"3.50.1"},"reference-count":22,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"unspecified","delay-in-days":75,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Chinese National Key Technology R&D Program"},{"DOI":"10.13039\/501100003711","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","award":["2022YFC2504600"],"award-info":[{"award-number":["2022YFC2504600"]}],"id":[{"id":"10.13039\/501100003711","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences","award":["2019XK32022"],"award-info":[{"award-number":["2019XK32022"]}]},{"name":"Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences","award":["2023-RW320-01"],"award-info":[{"award-number":["2023-RW320-01"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2024-I2M-C&T-B-005"],"award-info":[{"award-number":["2024-I2M-C&T-B-005"]}]},{"DOI":"10.13039\/501100001809","name":"Nation Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81501414"],"award-info":[{"award-number":["81501414"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2026,2,7]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the safety and durability of telitacicept treatment in patients with SLE by identifying the reasons for treatment discontinuation and potential risk factors for subsequent disease recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included 48 lupus patients who discontinued telitacicept and were under long-term follow-up at Peking Union Medical College Hospital. The underlying causes for treatment discontinuation and the subsequent disease outcomes were analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study found that, among 48 patients who discontinued telitacicept, 18 (37.5%, 18\/48) did so due to achieving a lupus low disease activity state (LLDAS), based on physician recommendations. Primary adverse discontinuation reasons included disease status changes necessitating treatment adjustment (16.7%, 8\/48), decreased immunoglobulin G levels (6.2%, 3\/48) and infection\/fever (6.2%, 3\/48). Among the 40 patients without changes to concomitant therapies post discontinuation, 30 (75%) maintained relatively stable Systemic Lupus Erythematosus Disease Activity Index scores, while 10 (25%) showed increased scores during the 12-month follow-up. Based on the characteristics at the time of telitacicept withdrawal, a high rate of central nervous system involvement was observed among patients who exhibited active disease after discontinuation. No significant fluctuations in serological markers were observed during the 12-month postdiscontinuation period (p&gt;0.05 for all comparisons).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The majority of patients (37.5%) discontinued telitacicept due to achieving LLDAS. During the 12-month follow-up after drug withdrawal, 75% (30\/40) of patients remained stable, whereas 25% had disease progression. A higher proportion of neurological involvement was observed in patients with disease changes after drug withdrawal, suggesting that patients with major organ involvement should be carefully evaluated following treatment cessation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/lupus-2025-001852","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T21:00:16Z","timestamp":1773867616000},"page":"e001852","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Twelve-month follow-up after telitacicept withdrawal in patients with SLE: a single-centre study"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1931-9483","authenticated-orcid":false,"given":"Zhaoyang","family":"Fan","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China"},{"name":"Department of Nephrology, School of Clinical Medicine, Shandong Second Medical University, Affiliated Hospital of Shandong Second Medical University, Weifang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunting","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Nephrology, School of Clinical Medicine, Shandong Second Medical University, Affiliated Hospital of Shandong Second Medical University, Weifang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Qiao","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangling","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nephrology, School of Clinical Medicine, Shandong Second Medical University, Affiliated Hospital of Shandong Second Medical University, Weifang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3484-4319","authenticated-orcid":false,"given":"Fengchun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0899-5703","authenticated-orcid":false,"given":"Li","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"2026031814001114000_13.1.e001852.1","doi-asserted-by":"crossref","first-page":"ITC81","DOI":"10.7326\/AITC202006020","article-title":"Systemic Lupus Erythematosus","volume":"172","author":"Kiriakidou","year":"2020","journal-title":"Ann Intern Med"},{"key":"2026031814001114000_13.1.e001852.2","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1038\/s41401-025-01554-2","article-title":"Immune cells in systemic lupus erythematosus: biology and traditional Chinese medicine therapy","volume":"46","author":"Liang","year":"2025","journal-title":"Acta Pharmacol Sin"},{"key":"2026031814001114000_13.1.e001852.3","first-page":"1671","article-title":"Telitacicept: First Approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs (Abingdon Engl)"},{"key":"2026031814001114000_13.1.e001852.4","doi-asserted-by":"crossref","first-page":"105704","DOI":"10.1016\/j.ejps.2021.105704","article-title":"Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLyS\/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis","volume":"159","author":"Yao","year":"2021","journal-title":"Eur J Pharm Sci"},{"key":"2026031814001114000_13.1.e001852.5","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"2026031814001114000_13.1.e001852.6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2026031814001114000_13.1.e001852.7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/1744666X.2023.2145281","article-title":"B cell depletion and inhibition in systemic lupus erythematosus","volume":"19","author":"Krustev","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"2026031814001114000_13.1.e001852.8","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.2147\/DDDT.S493923","article-title":"The Latest Progress in the Application of Telitacicept in Autoimmune Diseases","volume":"18","author":"Liu","year":"2024","journal-title":"Drug Des Devel Ther"},{"key":"2026031814001114000_13.1.e001852.9","doi-asserted-by":"publisher","DOI":"10.7326\/M21-2078"},{"key":"2026031814001114000_13.1.e001852.10","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224854"},{"key":"2026031814001114000_13.1.e001852.11","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2026031814001114000_13.1.e001852.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213032"},{"key":"2026031814001114000_13.1.e001852.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205067"},{"key":"2026031814001114000_13.1.e001852.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207653"},{"key":"2026031814001114000_13.1.e001852.15","doi-asserted-by":"publisher","DOI":"10.1002\/art.10461"},{"key":"2026031814001114000_13.1.e001852.16","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2020.1763793"},{"key":"2026031814001114000_13.1.e001852.17","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1007\/s10067-025-07571-0","article-title":"Discontinuation of belimumab in systemic lupus erythematosus patients who achieved disease stability: a retrospective cohort study","volume":"44","author":"Ren","year":"2025","journal-title":"Clin Rheumatol"},{"key":"2026031814001114000_13.1.e001852.18","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-025-03584-x","article-title":"Prospective analysis of B cell subset dynamics following telitacicept treatment in systemic lupus erythematosus","volume":"27","author":"Chen","year":"2025","journal-title":"Arthritis Res Ther"},{"key":"2026031814001114000_13.1.e001852.19","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/cpdd.1136","article-title":"Pharmacokinetic Characteristics, Safety, and Tolerability of Telitacicept, an Injectable Recombinant Human B-Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein, in Healthy Chinese Subjects","volume":"11","author":"Xie","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2026031814001114000_13.1.e001852.20","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/S2665-9913(23)00320-X","article-title":"Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial","volume":"6","author":"Chakravarty","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"2026031814001114000_13.1.e001852.21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1169084","article-title":"Telitacicept for autoimmune nephropathy","volume":"14","author":"Cai","year":"2023","journal-title":"Front Immunol"},{"key":"2026031814001114000_13.1.e001852.22","doi-asserted-by":"crossref","first-page":"114596","DOI":"10.1016\/j.intimp.2025.114596","article-title":"Efficacy and safety of telitacicept in patients with class III\u2013V lupus nephritis: A real-world retrospective cohort study","volume":"154","author":"Chen","year":"2025","journal-title":"Int Immunopharmacol"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2025-001852","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T21:00:19Z","timestamp":1773867619000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2025-001852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,18]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/lupus-2025-001852"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2025-001852","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}